I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
The Prescribing Clinical Network recommends Eltrombopag (Revolade®) in the following circumstances: - For initiation by specialists in Bone Marrow Transplant (BMT) centres ONLY, in patients with severe aplastic anaemia who are refractory to immunosuppressive therapy (IST) and where there is no suitably matched donor for haematopoietic stem cell transplantation (HSCT).
Eltrombopag will be considered RED on the traffic light system and specialists will be required to notify commissioners of treatment in line with PCN recommendations, using the tick box proformas on the Blueteq database.
